BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10991861)

  • 1. Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase.
    Suling WJ; Seitz LE; Pathak V; Westbrook L; Barrow EW; Zywno-Van-Ginkel S; Reynolds RC; Piper JR; Barrow WW
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2784-93. PubMed ID: 10991861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antifolate inhibitors for Mycobacterium avium.
    Barrow EW; Suling WJ; Seitz LE; Reynolds RC; Barrow WW
    Med Chem; 2006 Sep; 2(5):505-10. PubMed ID: 17017990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro.
    Suling WJ; Maddry JA
    J Antimicrob Chemother; 2001 Apr; 47(4):451-4. PubMed ID: 11266419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase.
    Suling WJ; Reynolds RC; Barrow EW; Wilson LN; Piper JR; Barrow WW
    J Antimicrob Chemother; 1998 Dec; 42(6):811-5. PubMed ID: 10052907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
    J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
    Chan DC; Fu H; Forsch RA; Queener SF; Rosowsky A
    J Med Chem; 2005 Jun; 48(13):4420-31. PubMed ID: 15974594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.
    Barrow EW; Dreier J; Reinelt S; Bourne PC; Barrow WW
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4447-52. PubMed ID: 17875993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of 2,4-diamino-6-(thioarylmethyl)pyrido[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
    Gangjee A; Adair O; Queener SF
    Bioorg Med Chem; 2001 Nov; 9(11):2929-35. PubMed ID: 11597474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
    Gangjee A; Elzein E; Queener SF; McGuire JJ
    J Med Chem; 1998 Apr; 41(9):1409-16. PubMed ID: 9554874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of new 2,4-Diaminopyrido[2,3-d]pyrimidine and 2,4-Diaminopyrrolo[2,3-d]pyrimidine inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
    Rosowsky A; Chen H; Fu H; Queener SF
    Bioorg Med Chem; 2003 Jan; 11(1):59-67. PubMed ID: 12467708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding mode analysis of 2,4-diamino-5-methyl-5-deaza-6-substituted pteridines with Mycobacterium tuberculosis and human dihydrofolate reductases.
    da Cunha EF; Ramalho TC; Reynolds RC
    J Biomol Struct Dyn; 2008 Feb; 25(4):377-85. PubMed ID: 18092832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
    Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
    J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
    Rosowsky A; Cody V; Galitsky N; Fu H; Papoulis AT; Queener SF
    J Med Chem; 1999 Nov; 42(23):4853-60. PubMed ID: 10579848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF
    J Med Chem; 1997 Feb; 40(4):479-85. PubMed ID: 9046338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2002 Jan; 45(1):233-41. PubMed ID: 11754594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
    J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.